BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 24369899)

  • 21. Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606.
    Mancini M; Brusa G; Zuffa E; Corrado P; Martinelli G; Grafone T; Barbieri E; Santucci MA
    Leuk Res; 2007 Jul; 31(7):979-87. PubMed ID: 17129604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
    Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
    Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Src, Akt, NF-κB, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia.
    Vázquez-Franco JE; Reyes-Maldonado E; Vela-Ojeda J; Domínguez-López ML; Lezama RA
    Leuk Res; 2012 Jul; 36(7):862-7. PubMed ID: 22591684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Expression of plk-1 gene in acute leukemia patients and its significance].
    Mao HW; Liu WL; Zhou JF; Sun HY; Xu HZ; Luo XH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct; 14(5):876-9. PubMed ID: 17096880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT).
    Ozawa Y; Williams AH; Estes ML; Matsushita N; Boschelli F; Jove R; List AF
    Leuk Res; 2008 Jun; 32(6):893-903. PubMed ID: 18179820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations.
    Robinson LJ; Xue J; Corey SJ
    Exp Hematol; 2005 Apr; 33(4):469-79. PubMed ID: 15781338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effects of TGF-beta 1 on normal and leukemic human hematopoietic cell proliferation.
    Murohashi I; Endho K; Nishida S; Yoshida S; Jinnai I; Bessho M; Hirashima K
    Exp Hematol; 1995 Aug; 23(9):970-7. PubMed ID: 7543418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Studies on CFU-Mix in 54 cases of leukemia and myelodysplastic syndrome].
    Chen Y; Wang BM; Li CY
    Zhonghua Nei Ke Za Zhi; 1989 Jan; 28(1):35-8, 62-3. PubMed ID: 2737036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of Fgr protein-tyrosine kinase is reduced in neutrophils of patients with myelodysplastic syndromes and chronic myelogenous leukemia.
    Kohno T; Katamine S; Moriuchi R; Miyamoto T; Tomonaga M
    Leuk Res; 1996 Mar; 20(3):221-7. PubMed ID: 8637216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
    Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
    Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children.
    Xu F; Taki T; Yang HW; Hanada R; Hongo T; Ohnishi H; Kobayashi M; Bessho F; Yanagisawa M; Hayashi Y
    Br J Haematol; 1999 Apr; 105(1):155-62. PubMed ID: 10233379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.
    Fialin C; Larrue C; Vergez F; Sarry JE; Bertoli S; Mansat-De Mas V; Demur C; Delabesse E; Payrastre B; Manenti S; Roche S; Récher C
    Leukemia; 2013 Feb; 27(2):325-35. PubMed ID: 22902361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells.
    Drexler HG; Quentmeier H
    Leukemia; 1996 Sep; 10(9):1405-21. PubMed ID: 8751457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
    Larsson N; Billström R; Lilljebjörn H; Lassen C; Richter J; Ekblom M; Fioretos T
    Cancer Genet Cytogenet; 2010 Jun; 199(2):89-95. PubMed ID: 20471511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
    Danhauser-Riedl S; Warmuth M; Druker BJ; Emmerich B; Hallek M
    Cancer Res; 1996 Aug; 56(15):3589-96. PubMed ID: 8758931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transcriptional down-regulation of the Wnt antagonist SFRP1 in haematopoietic cells of patients with different risk types of MDS.
    Reins J; Mossner M; Neumann M; Platzbecker U; Schumann C; Thiel E; Hofmann WK
    Leuk Res; 2010 Dec; 34(12):1610-6. PubMed ID: 20471677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idarubicin induces mTOR-dependent cytotoxic autophagy in leukemic cells.
    Ristic B; Bosnjak M; Arsikin K; Mircic A; Suzin-Zivkovic V; Bogdanovic A; Perovic V; Martinovic T; Kravic-Stevovic T; Bumbasirevic V; Trajkovic V; Harhaji-Trajkovic L
    Exp Cell Res; 2014 Aug; 326(1):90-102. PubMed ID: 24907655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
    Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
    Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
    O'Hare T; Walters DK; Stoffregen EP; Sherbenou DW; Heinrich MC; Deininger MW; Druker BJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6987-93. PubMed ID: 16203792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.